StreetInsider.com News Articles

Form 144 Mineralys Therapeutics, Filed by: Rodman David Malcom

Tue, 13 Oct 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20261013/27181217.html

H.C. Wainwright Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

Mon, 12 Oct 2026 06:52:33 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $56.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).

The analyst commented: 'Mineralys Therapeutics presented new data for aldosterone synthase inhibitor (ASI) lorundrostat at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, adding to the clinical evidence supporting lorundrostat’s potential in difficult-to-treat hypertension. We view the latest findings as constructive ahead of the approaching December 22, 2026, PDUFA, supporting lorundrostat’s profile for delivering clinically meaningful BP reductions in patients who remain above target despite multiple standard anti-hypertensive therapies. Importantly, the new Launch-HTN analysis provides a more tangible perspective on the

UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral

Mon, 12 Oct 2026 02:24:10 -0400

UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Neutral rating and a price target of $29.00.

The analyst comments: “We initiate coverage of Mineralys (MLYS) with a Neutral rating, and $29 PT. MLYS's lorundrostat (lor), an aldosterone synthase inhibitor (ASI) for later-line hypertension (HTN), is under FDA review and, if approved, is positioned for a commercial launch in late '26/early '27. We believe lor can become a meaningful product, supported by a large HTN oppy, strong Phase 3 data, and the potential for ASI indication expansion. Nonetheless, in our view, the stock is likely to

UBS Starts Mineralys Therapeutics, Inc. (MLYS) at Neutral

Mon, 12 Oct 2026 02:24:10 -0400

UBS analyst Alice Nettleton initiates coverage on Mineralys Therapeutics, Inc. (NASDAQ: MLYS) with a Neutral rating and a price target of $29.00.

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Fri, 09 Oct 2026 09:00:00 -0400

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of <130 mmHg at 12 weeks, with more than two-thirds achieving ≥10 mmHg systolic blood pressure reduction -

- In the Explore-OSA trial in participants with obstructive sleep apnea, lorundrostat 50 mg taken once daily in the evening achieved clinically meaningful reductions in morning systolic blood pressure with no measurable change in apnea-hypopnea indices -

RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

Fri, 09 Oct 2026 09:00:00 -0400

RADNOR, Pa., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.

Form 4 Mineralys Therapeutics, For: Sep 30 Filed by: Congleton Jon

Fri, 02 Oct 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20261002/27143783.html

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Fri, 02 Oct 2026 16:30:00 -0400

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that new data from the Launch-HTN trial of lorundrostat will be presented at the American Society of Nephrology Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

Oral Presentation Details:

Title:

Blood Pressure

Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

Fri, 02 Oct 2026 16:30:00 -0400

Oral Presentation Details:

Title:

Blood Pressure

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Thu, 01 Oct 2026 16:05:00 -0400

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that five abstracts will be presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2026, taking place October 7-11 in Arlington, VA.

Oral Presentation Details:

Title:

Efficacy and Safety of the Selective

Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026

Thu, 01 Oct 2026 16:05:00 -0400

Oral Presentation Details:

Title:

Efficacy and Safety of the Selective

Form 144 Mineralys Therapeutics, Filed by: Congleton Jon

Wed, 30 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260930/27128729.html

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:05:00 -0400

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees.

The awards were granted under

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Tue, 29 Sep 2026 16:05:00 -0400

The awards were granted under

Form 4 Mineralys Therapeutics, For: Sep 22 Filed by: Slingsby Brian Taylor

Mon, 28 Sep 2026 11:50:00 -0400

si-local-file:///var/storage/secattach/20260928/27112147.html

Form 4 Mineralys Therapeutics, For: Sep 22 Filed by: Slingsby Brian Taylor

Thu, 24 Sep 2026 21:50:00 -0400

si-local-file:///var/storage/secattach/20260924/27103274.html

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Thu, 24 Sep 2026 16:05:00 -0400

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026.

Stifel 2026 Virtual Cardiometabolic Forum
Date:		Wednesday, September 30, 2026
Time:		12:00pm ET
Format:		Fireside Chat

A live webcast of this fireside chat can

Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

Thu, 24 Sep 2026 16:05:00 -0400

Stifel 2026 Virtual Cardiometabolic Forum
Date:		Wednesday, September 30, 2026
Time:		12:00pm ET
Format:		Fireside Chat

A live webcast of this fireside chat can

Mineralys trial data to be presented at AHA Scientific Sessions in November

Wed, 23 Sep 2026 16:06:05 -0400

Mineralys Therapeutics (Nasdaq: MLYS) announced that long-term efficacy and safety data from its ongoing Transform-HTN open-label extension trial of lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, scheduled for November 6-9 in Chicago.

The presentation, titled "Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension," is set for November 8 at 3:30 p.m. CT. Manish Saxena, Deputy Clinical Co-Director of Queen Mary University of London's William Harvey Heart Centre and a hypertension specialist at Barts Health NHS Trust, will present the data.

Transform-HTN (NCT05968430) is a global

Mineralys trial data to be presented at AHA Scientific Sessions in November

Wed, 23 Sep 2026 16:06:05 -0400

Transform-HTN (NCT05968430) is a global

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Wed, 23 Sep 2026 16:05:00 -0400

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.

Details for the Presentation:

Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

Wed, 23 Sep 2026 16:05:00 -0400

Details for the Presentation:

Form 4 Mineralys Therapeutics, For: Sep 21 Filed by: Warren Eric

Tue, 22 Sep 2026 18:49:00 -0400

si-local-file:///var/storage/secattach/20260922/27092117.html

Form 144 Mineralys Therapeutics, Filed by: Rodman David Malcom

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091831.html

Form 144 Mineralys Therapeutics, Filed by: Catalys Pacific Fund, LP

Tue, 22 Sep 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091140.html